105211-78-7

Basic information

• Product Name: 4-HYDROXY-3-PROPYLBENZOIC ACID METHYL ESTER
• Synonyms: 4-HYDROXY-3-PROPYLBENZOIC ACID METHYL ESTER;4-Hydroxy-3-propylbenzoicacidmethylester95%;4-HYDROXY-3-PROPYLBENZOIC ACID METHYL ESTER 95%;Methyl 4-hydroxy-3-propylbenzoate
• CAS NO: 105211-78-7
• Molecular Formula: C₁₁H₁₄O₃
• Molecular Weight: 194.23
• EINECS: 604-604-1
• Mol File: 105211-78-7.mol
• Article Data: 6

Chemical Properties

• Boiling Point: 315.2 °C at 760 mmHg
• Flash Point: 132.5 °C
• Appearance: /
• Density: 1.109 g/cm³
• Vapor Pressure: 0.00024mmHg at 25°C
• Refractive Index: 1.53
• Storage Temp.: 2-8°C
• PKA: 8.88±0.18(Predicted)
• CAS DataBase Reference: 4-HYDROXY-3-PROPYLBENZOIC ACID METHYL ESTER(CAS DataBase Reference)
• NIST Chemistry Reference: 4-HYDROXY-3-PROPYLBENZOIC ACID METHYL ESTER(105211-78-7)
• EPA Substance Registry System: 4-HYDROXY-3-PROPYLBENZOIC ACID METHYL ESTER(105211-78-7)

Safety Data

• Hazard Codes: Xn
• Statements: 22
• Hazardous Substances Data: 105211-78-7(Hazardous Substances Data)

Usage

General Description

4-HYDROXY-3-PROPYLBENZOIC ACID METHYL ESTER is a chemical compound with the molecular formula C10H12O3. It is commonly used as a fragrance and flavoring agent in the food and cosmetics industries. This chemical is a clear, colorless liquid with a faint, sweet odor, and it is soluble in alcohol and ether. Its primary function is to enhance the aroma and taste of various products. Additionally, it is used in the production of pharmaceuticals, plastics, and other industrial applications. However, it is important to handle and store this compound with care, as it can be hazardous if not properly managed.

InChI:InChI=1/C11H14O3/c1-3-4-8-7-9(11(13)14-2)5-6-10(8)12/h5-7,12H,3-4H2,1-2H3

Upstream product

• 35750-24-4 methyl 4-allyloxybenzoate 
• 99-76-3 methyl 4-hydroxylbenzoate 
• 53596-60-4 methyl 3-allyl-4-hydroxybenzoate 

Downstream Products

• 159591-45-4 ethyl α-(4-carbomethoxy-2-n-propylphenoxy)-3,4-methylenedioxyphenylacetate 
• 159590-92-8 α-(4-carbomethoxy-2-n-propylphenoxy)-3,4-methylenedioxyphenylacetic acid 
• 1031393-43-7 3-(4-(4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)-2-n-propylphenoxy)butyl)-1,5,5-trimethylimidazolidine-2,4-dione 
• 1031401-04-3 1-(4-bromobutoxy)-4-(1,1,1,3,3,3-hexafluoro-2-(methoxymethoxy)propan-2-yl)-2-n-propylbenzene 
• 1031400-93-7 1-(benzyloxy)-4-(1,1,1,3,3,3-hexafluoro-2-(methoxymethoxy)propan-2-yl)-2-n-propylbenzene 
• 1031393-40-4 3-[4-[4-[1,1,1,3,3,3-hexafluoro-2-(methoxymethyl)oxypropan-2-yl]-2-propylphenyloxy]butyl]-1,5,5-trimethylimidazolidine-2,4-dione 
• 1031393-25-5 4-(1,1,1,3,3,3-hexafluoro-2-(methoxymethoxy)propan-2-yl)-2-n-propylphenol 
• 1031400-91-5 2-(4-(benzyloxy)-3-n-propylphenyl)-1,1,1,3,3,3-hexafluoropropan-2-ol 
• 1031400-97-1 4-(1,1,1,3,3,3-hexafluoro-2-(methoxymethoxy)propan-2-yl)-2,6-di-n-propylphenol 
• 1031396-25-4 5-(benzo[d][1,3]dioxol-5-yl)-5-ethyl-3-(4-(4-(1,1,1,3,3,3-hexafluoro-2-hydroxy-propan-2-yl)-2,6-di-n-propylphenoxy)butyl)imidazolidine-2,4-dione 
• 1031396-22-1 5-ethyl-3-(4-(4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)-2,6-di-n-propyl-phenoxy)butyl)-5-(4-methoxyphenyl)imidazolidine-2,4-dione 
• 1031395-90-0 5-([1,1'-biphenyl]-4-yl)-3-(4-(4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)-2,6-di-n-propylphenoxy)butyl)-5-methylimidazolidine-2,4-dione 
• 1031395-50-2 3-(4-(4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)-2,6-di-n-propylphenoxy)-butyl)-5-(4-isopropylphenyl)-5-methylimidazolidine-2,4-dione 
• 1031396-07-2 5-(2,3-dihydrobenzo[b][1,4]dioxin-6-yl)-3-(4-(4-(1,1,1,3,3,3-hexafluoro-2-hydroxy-propan-2-yl)-2,6-di-n-propylphenoxy)butyl)-5-methylimidazolidine-2,4-dione 

Relevant articles and documents

DEUTERIUM-ENRICHED SUBSTITUTED PHENOXYPHENYL ACETIC ACIDS AND ACYLSULFONAMIDES

The present invention is concerned with deuterium-enriched substituted phenoxy-(3, 4-methylenedioxy)phenylacetic acid and acylsulfonamide derivatives of general structural formula I, their optically active or pure enantiomers and diastereomers, and pharmaceutical salts thereof, Formula (I) These compounds have selective antagonist activity for endothelin receptors or both endothelin and angiotensin II receptors, and are useful in the treatment of diseases mediated by endothelin and angiotensin-II and their receptors.

CARBINOL DERIVATIVES HAVING CYCLIC LINKER

[Object] To provide a novel LXRβ agonist that is useful as a preventative and/or therapeutic agent for atherosclerosis; arteriosclerosis such as those resulting from diabetes; dyslipidemia; hypercholesterolemia; lipid-related diseases; inflammatory diseases that are caused by inflammatory cytokines; skin diseases such as allergic skin diseases; diabetes; or Alzheimer's disease. [Solving Means] A carbinol compound represented by the following general formula (I) or salt thereof, or their solvate.

THROMBIN INHIBITORS

A compound which inhibits human thrombin and which has the general structure STR1